Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
M.D. Anderson Cancer Center
GlaxoSmithKline
National Cancer Institute (NCI)
AstraZeneca
Eisai Inc.
AstraZeneca
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
BioNTech SE
Gilead Sciences
Merck Sharp & Dohme LLC
Faeth Therapeutics
AstraZeneca
GlaxoSmithKline
Fate Therapeutics
Washington University School of Medicine
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Bio-Thera Solutions
Leap Therapeutics, Inc.
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
GlaxoSmithKline
Danish Gynecological Cancer Group
University of Maryland, Baltimore
Eisai Inc.
Yonsei University
Merck Sharp & Dohme LLC
Mario Negri Institute for Pharmacological Research
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Huabo Biopharm Co., Ltd.
Hutchmed
Washington University School of Medicine
Peking Union Medical College Hospital
Leiden University Medical Center
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
NETRIS Pharma
BioMimetix JV, LLC
Sohag University
Zhongnan Hospital
Huazhong University of Science and Technology
University of Oklahoma
Sun Yat-sen University
Fujian Cancer Hospital